Advancement in Heart Failure

 

The prevalence of heart failure (HF) continues to increase over time1 and affects >60 million people each year2.

 

Therefore, being aware of the latest data in the HF space and different treatment options is important in order to be able to apply findings to clinical practice when making treatment decisions for patients with type 2 diabetes mellitus (T2DM) and cardiovascular disease, especially HF.

Close X
Other videos you might like

This section is supported by the Boehringer Ingelheim & Lilly Alliance

Recent Videos

Video

ESC 2021 Discussion: The EMPEROR-Pooled Study
Milton Packer, Harriette Van Spall

Video Series

SGLT-2 Inhibitors in Heart Failure: Putting the Evidence Into Practice
Andrew JS Coats, Giuseppe Rosano

Video

ESC 2021 Discussion: The EMPEROR-Preserved Trial
Stefan Anker, Harriette Van Spall

Video Series

SGLT2i Updates 2021
Stefan Anker, Shelley Zieroth, Andrew JS Coats

Video

ACC 21: Benefits of SGLT1/2 Inhibition Across the Full Spectrum of EF
Deepak Bhatt, Harriette Van Spall

Video Series

Optimising Treatment of HF
Shelley Zieroth, Martin R Cowie, Javed Butler
Asymptomatic Left Ventricle Systolic Dysfunction

European Cardiology Review 2020;15:e13.

Heart Failure Treatment by Device

European Cardiology Review 2020;15:e17.

Interatrial Shunting for Treating Acute and Chronic Left Heart Failure

European Cardiology Review 2020;15:e18.

Destination Therapy with Left Ventricular Assist Devices in Non-transplant Centres: The Time is Right

European Cardiology Review 2020;15:e19.

Contemporary Management of Secondary Mitral Regurgitation

European Cardiology Review 2020;15:e22.

Corrigendum to: Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments

European Cardiology Review 2019;14(3):201

Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments

European Cardiology Review 2019;14(1):23-32

Cardiac Resynchronisation Therapy and Cellular Bioenergetics: Effects Beyond Chamber Mechanics

European Cardiology Review 2019;14(1):33–44

Testosterone and the Heart

European Cardiology Review 2019;14(2):103–10

Left Ventricular Ejection Fraction in Heart Failure

European Cardiology Review 2018;13(2):91–2.

Cavin-2 Deficiency Attenuates Cardiac Fibrosis and Dysfunction in Pressure-overloaded Hearts

European Cardiology Review 2018;13(2):120.

Analysis of the Effects of EPA and DHA on Cardiomyocyte hypertrophy

European Cardiology Review 2018;13(2):121.

The GATA4 Acetylation Site Plays a Key Role in the Development of Cardiomyocyte Hypertrophy

European Cardiology Review 2018;13(2):125.

TBL1 Suppresses Cardiomyocyte Hypertrophy by Regulating the Interaction Between HDAC3 and GATA4

European Cardiology Review 2018;13(2):126.

The Role of p53 Localised in Cytosol and Mitochondria During Reprogramming to iPS Cells

European Cardiology Review 2018;13(2):127.

The Mechanism of Hey2 Expression in Cardiac Development

European Cardiology Review 2018;13(2):128.

Cardiovascular Implications of Sphingomyelin Presence in Biological Membranes

European Cardiology Review 2018;13(1):42–5.

Curcumin Analogue GO-Y030 Significantly Improves Pressure Overload-induced Heart Failure in Vivo

European Cardiology Review 2017;12(2):106.

The Inhibitory Effects of Curcumin Glucuronide on p300-HAT Activity and Hypertrophic Phenylephrine-Induced Responses in Cardiomyocytes

European Cardiology Review 2017;12(2):107.

A Transcriptional Co-activator, p300 is Involved in the Epigenetic Gene Activation on Hypertrophic Response Gene Promoters in Heart Failure

European Cardiology Review 2017;12(2):110.

Analysis of Factors Associated with Smoking Relapse

European Cardiology Review 2017;12(2):111.

Role of Testosterone in the Treatment of Cardiovascular Disease

European Cardiology Review 2017;12(2):83–7

Inflammation Revisited: Atherosclerosis in The Post-CANTOS Era

European Cardiology Review 2017;12(2):89–91

Hypertrophic Cardiomyopathy in Athletes

European Cardiology Review 2017;12(2):80–2

Cardiovascular Risk Management Targeting Inflammation in Addition to Lipid-lowering Therapy

European Cardiology Review 2017;12(2):88

Nobiletin a Citrus Flavonoid, Exerts Additional Effects with Angiotensin II Receptor Blocker on Systolic Function in Salt-sensitive Dahl Rats

European Cardiology Review 2017;12(2):92.

Cardiac Resynchronization is Associated with Reduction in the Rate of ICD Therapies, While Improves Ventricular Function

European Cardiology Review 2017;12(2):93.

Effects of Pharmacotherapy for Smoking Cessation on LOX Index, a Cardiovascular Risk Marker

European Cardiology Review 2017;12(2):96.

5-Year Outcomes After Implementation of Optimal Medical Therapy in General Practice Using Liaison Critical Pathway for Secondary Prevention of Coronary Artery Disease: An Observational Study

European Cardiology Review 2017;12(2):98.

A Risk Score to Predict the Absence of Left Ventricular Reverse Remodelling: Implications for the Timing of ICD Implantation in Primary Prevention

European Cardiology Review 2017;12(2):99.

Secondary Prevention in Patients with Non Valvular Atrial Fibrillation and Previous Stroke. Is It Possible to Have an Appropriate INR Control?

European Cardiology Review 2017;12(2):103.

Consensus is Possible: Initiation and Exchange of Oral Anticoagulants in Non-valvular Atrial Fibrillation, According to a Territorial Protocol in a Period of Time

European Cardiology Review 2017;12(2):104.

A Novel Target Molecule of Nobiletin Derived from Citrus Peels has a Therapeutic Potency Against the Development of Heart Failure

European Cardiology Review 2017;12(2):105.

Sleep-disordered Breathing in Heart Failure

European Cardiology Review 2015;10(2):89–94

Cardiac Amyloid – An Update

European Cardiology Review 2015;10(2):113–7

A Practical Clinical Approach to the Diagnosis and Treatment of Patients with Pulmonary Hypertension

European Cardiology Review 2015;10(2):102–7

Sudden Cardiac Death Risk Stratification – An Update

European Cardiology Review 2015;10(2):118–22

Risk Stratification in Hypertrophic Cardiomyopathy

European Cardiology Review 2015;10(1):31–6

Chemotherapy-related Cardiomyopathy

European Cardiology Review 2015;10(1):19–24

Diuretic Therapy in Heart Failure – Current Approaches

European Cardiology Review 2015;10(1):42–7

The Diagnosis and Clinical Implications of Interatrial Block

European Cardiology Review 2015;10(1):54–9

Sudden Cardiac Death in Athletes

European Cardiology Review 2015;10(1):48–53

Takotsubo Syndrome – Stress-induced Heart Failure Syndrome

European Cardiology Review 2015;10(2):83–8

Home Orthostatic Training in Elderly Patients with Vasovagal Syncope – A Prospective Randomised Controlled Trial

European Cardiology Review 2015;10(2):123–7

Wall Motion Tracking and Activation Imaging - Latest Developments and Applications for Patients with Heart Failure

European Cardiology 2012;8(1):51-5

Pharmacological Treatment of Patients with Chronic Systolic Heart Failure

European Cardiology Review 2014;9(1):43–8

Diabetes Mellitus and Heart Failure

European Cardiology Review 2014;9(1):37–42

Mitral Regurgitation – A Multidisciplinary Challenge

European Cardiology Review 2014;9(1):49–53

Ventricular Assist Devices – Evolution of Surgical Heart Failure Treatment

European Cardiology Review 2014;9(1):54–8

The Brugada Syndrome – Diagnosis, Clinical Implications and Risk Stratification

European Cardiology Review 2014;9(2):82–7

Gaps in the Heart Failure Guidelines

European Cardiology Review 2014;9(2):104–9

Update on Cardiac Resynchronisation Therapy for Heart Failure

European Cardiology Review 2014;9(2):100–3

Novel Biomarkers in Heart Failure Beyond Natriuretic Peptides — The Case for Soluble ST2

European Cardiology Review 2015;10(1):37–41

Cardiac Transplantation - Status in 2011

European Cardiology 2011;7(4):273–9

Managing Hyponatraemia in Heart Failure

European Cardiology 2008;4(2):39–41

Preventing Sudden Cardiac Death in Patients with Ischaemic Cardiomyopathy

European Cardiology 2012;8(2):134-8

Telemonitoring in Patients with Heart Failure - Lessons from Recent Randomised Multicentre Trials

European Cardiology 2012;8(2):84-7

Measuring Left Ventricular Ejection Fraction - Techniques and Potential Pitfalls

European Cardiology 2012;8(2):108-14

Assessing Acute Decompensated Heart Failure - Strategies and Tools

European Cardiology 2012;8(2):128-33

Heart Failure with Preserved Ejection Fraction - A Review

European Cardiology 2012;8(3):186–91

Transvenous Phrenic Nerve Stimulation - A Novel Therapy for Central Sleep Apnoea in Heart Failure

European Cardiology 2012;8(1):44-7

Using Natriuretic Peptides to 'Guide' Therapy in Heart Failure

European Cardiology 2012;8(1):36-9

Sleep-disordered Breathing and Heart Failure - Insights from Speckle Tracking Echocardiography

European Cardiology 2012;8(1):40-3

The Evolution of Ventricular Assist Devices and the HeartWare® Ventricular Assist System

European Cardiology 2012;8(1):32-5

The Use of an Absorbable Microporous Polysaccharide Hemosphere Haemostat (AristaAH) in Ventricular Assist Device Implant and Cardiac Transplantation Procedures

European Cardiology 2011;8(2):125-7

Diastolic Heart Failure - Are Treatment Options Available?

European Cardiovascular Disease 2006;2(2):73–5

The Use of B-type Natriuretic Peptide in Clinical Practice

European Cardiovascular Disease 2006;2(1):37–9

Echocardiography in the Detection and Monitoring of Heart Failure

European Cardiovascular Disease 2006;2(1):53–6

The Role of Beta Blockade in Heart Failure

European Cardiology 2005;1(1):58-60

Inhibition of the Late Sodium Current with Ranolazine - A New Cardioprotective Mechanism

European Cardiology 2008;4(2):46–8

Comparison of B-type Natriuretic Peptide and N-terminal proBNP in Daily Clinical Practice

European Cardiology 2008;4(2):35–8

Cardiac Iodine-123 Metaiodobenzylguanidine Imaging for Risk Stratification in Heart Failure Patients

European Cardiology 2008;4(2):42–5

B-type Natriuretic Peptides in the Management of Acute Heart Failure and Acute Coronary Syndromes

European Cardiovascular Disease 2007;3(2):22–3

Tako-tsubo Cardiomyopathy in Patients with Intracerebral Haemorrhage

European Cardiovascular Disease 2006;2(2):70–2

Amino-terminal Pro-brain Natriuretic Peptide Testing - Recent Lessons Learned

European Cardiovascular Disease 2006;2(2):20–4

Monitoring Heart Failure using an Implantable Device Measuring Intrathoracic Impedance - Technical and Clinical Overview

European Cardiology 2005;1(1):62-5

Multidetector-row Computed Tomography in the Assessment of Coronary Artery Disease - New Techniques and Insights

European Cardiology 2010;6(2):43–7

Myocardial Metabolic Imaging in the Clinical Setting

European Cardiology 2009;5(1):15–8

Controversies in Implantable Cardioverter-defibrillator Therapy

European Cardiology 2011;7(3):199–202

Non-pharmacological Management and Patient Education in Heart Failure Patients

European Cardiovascular Disease 2006;2(1):108–10

Natriuretic Peptides - Addressing the Dilemma of Heart Failure Management

European Cardiology 2011;7(2):104–7

Ion Channel Remodelling in Atrial Fibrillation

European Cardiology 2011;7(2):97–103

Baroreflex Sensitivity Assessment - Latest Advances and Strategies

European Cardiology 2011;7(2):89–92

Chronic Mechanical Circulatory Support for Patients with End-stage Heart Failure as a Definitive Treatment Option

European Cardiology 2010;6(4):22–5

Telemonitoring in Heart Failure Rehabilitation

European Cardiology 2011;7(1):66–9

Galectin-3 in Heart Failure - Linking Fibrosis, Remodeling, and Progression

European Cardiology 2010;6(2):33–6

Histopathological Changes and Clinical Implications in Patients with Hypertrophic Cardiomyopathy

European Cardiology 2010;6(2):88–90

Risk Stratification in Post-myocardial Infarction Patients

European Cardiology 2010;6(3):22–6

Diagnosing Heart Failure: Experience and ‘Best Pathways’

European Cardiology 2010;6(3):10–2

Echocardiographic Assessment of Diastolic Heart Failure

European Cardiology 2010;6(3):13–7

Monitoring Heart Failure using an Implantable Device Measuring Intrathoracic Impedance - Technical and Clinical Overview

European Cardiology 2005;1(1):1-4

New Echocardiographic Modalities in the Detection and Monitoring of Heart Failure -The Clinical Potential of Speckle-tracking Technology

European Cardiovascular Disease 2007;3(1):115–8

Atrial Fibrillation in Heart Failure Patients

European Cardiology 2009;5(1):41–5

Atrial Fibrillation in the Failing Heart - A Clinical Review

European Cardiology 2010;6(1):75–9

Beyond the Apnoea-Hypopnoea Index - Prognostic Value of Other Elements of Polysomnography to Describe Sleep-disordered Breathing in Heart Failure

European Cardiology 2009;5(2):53–6

Cardiac Resynchronisation Therapy - Evolving Strategies to Enhance Response

European Cardiology 2010;6(1):83–7

Cardiac Resynchronisation Therapy in Chronic Heart Failure

European Cardiology 2005;1(1):1-5

Stress Echocardiography - Current Status

European Cardiology 2005;1(1):1-5

Phosphodiesterase-5 Inhibition in Chronic Heart Failure - An Emerging Therapeutic Opportunity

European Cardiology 2008;4(1):28–30

Heart Failure with Preserved Ejection Fraction

European Cardiology 2008;4(1):31–3

Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death

European Cardiology 2010;6(3):92–6

Statin Therapy in Patients with Diastolic Heart Failure - Time for a Large, Randomised Study?

European Cardiovascular Disease 2007;3(1):120–2

An Update on N-terminal Pro-Brain-type Natriuretic Peptide for Risk Stratification in Chronic Heart Failure

European Cardiovascular Disease 2007;3(1):35–8

Atrial Fibrillation in the Setting of Heart Failure

European Cardiology 2010;6(2 Suppl):13–6

Cardiac Resynchronisation Therapy in Heart Failure Patients with Atrial Fibrillation

European Cardiology 2010;6(2):92–5

Prognostic Significance of NTproBNP in Patients with a Clinical Diagnosis of Heart Failure and Preserved Left Ventricular Systolic Function

European Cardiovascular Disease 2007;3(1):41–2

Natriuretic Peptides - A Review

European Cardiology 2005;1(1):66-9

The Use of B-type Natriuretic Peptide in Clinical Practice

European Cardiovascular Disease 2006;2(1):1–4

The Role of Beta Blockade in Heart Failure

European Cardiology 2005;1(1):1-6

The Treatment and Diagnosis of Decompensated Heart Failure

European Cardiovascular Disease 2006;2(1):105

Treatment of Acute Heart Failure - What We Have Learned to Date and How to Put it Into Practice

European Cardiovascular Disease 2006;2(1):100–2

Treatment of Decompensated Heart Failure

Echocardiography in the Detection and Monitoring of Heart Failure

European Cardiovascular Disease 2006;2(1):1–6

Emerging Cardiac Resynchronisation Therapy Indications

Eurpoean Cardiology 2011;7(1):29–33

Dynamic Bi-level Positive Airway Pressure Ventilation for the Treatment of Central Sleep Apnoea in Patients with Chronic Heart Failure

European Cardiovascular Disease 2006;2(1):106

1.Heart disease and stroke statistics-2020 update: a report from the American Heart Association
Virani SS, Alonso A, Benjamin EJ, et al. Circulation 2020;141:e139-e596.
https://doi.org/10.1161/CIR.0000000000000757

2. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Lancet 2017;390:1211-59.
https://doi.org/10.1016/S0140-6736(17)32154-2